eligibility_summary
Eligible: patients with advanced/metastatic solid tumors, measurable/evaluable disease (RECIST 1.1), ECOG 0–1, life expectancy >3 months. Exclude: other malignancy within 2 years, prior MDS/AML, significant cardiovascular disease within 6 months, significant GI disease, HIV with CD4<200 or detectable viral load, or liver dysfunction.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
- Interventions: SNV1521 (investigational oral small‑molecule tablet, precise mechanism not disclosed in the registry) tested alone and with trastuzumab deruxtecan (T‑DXd), a HER2‑directed antibody–drug conjugate. - Mechanisms: T‑DXd binds HER2 on tumor cells via trastuzumab, blocks HER2 signaling and mediates ADCC, is internalized, and releases a topoisomerase I inhibitor payload (deruxtecan) causing DNA damage and cell death (including a bystander effect). The specific molecular target/pathway of SNV1521 is not specified. - Target cells/pathways: HER2‑expressing tumor cells (for T‑DXd), with downstream effects on HER2 signaling and DNA replication/repair via topo I inhibition. SNV1521’s targeted cell population/pathway not disclosed. The trial includes dose escalation/expansion and a combination arm, expansions include mCRPC, PDAC, and tumors with brain metastases.